Skip to content

Study · In vitro (cells) · grass carp (receptor) · 2017

3 results

Molecular cloning, tissue distribution, and pharmacological characterization of melanocortin-4 receptor in grass carp (Ctenopharyngodon idella).

Li L, Yang Z, Zhang YP, He S, Liang XF, Tao YX

Domestic animal endocrinology21 Nov 2016Cited by 25 (Europe PMC)

PMID28152402 (opens in a new tab)DOI10.1016/j.domaniend.2016.11.004 (opens in a new tab)PepBankPUB-28152402
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In assays of grass carp MC4R, NDP-MSH bound the receptor with the highest affinity of the 4 agonists tested.

    In plain wordsIn lab tests, NDP-MSH bound the grass carp MC4R receptor more strongly than the other three agonists tested.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableBinding affinity to grass carp MC4R
    Study

    grass carp (receptor)n: not reported in source

    grass carp MC4R (ciMC4R) pharmacological assays
    Comparator
    alpha-MSH, beta-MSH, ACTH
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Grass carp MC4R had the highest affinity for NDP-MSH.
    1 context sentence
    Summary · context
    The pharmacological properties of ciMC4R were investigated using 4 agonists, including α-melanocyte stimulating hormone (α-MSH), β-MSH, [Nle4, D-Phe7]-MSH (NDP-MSH), and adrenocorticotropic hormone (ACTH).
  2. 02LabIn vitro (cells)Activity measurement

    In assays of grass carp MC4R, NDP-MSH bound the receptor and caused dose-dependent intracellular cAMP accumulation.

    In plain wordsIn lab tests, NDP-MSH increased cAMP in a dose-dependent way through the grass carp MC4R receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasecAMP accumulation via grass carp MC4R
    Study

    grass carp (receptor)n: not reported in source

    grass carp MC4R (ciMC4R) pharmacological assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that all 4 ligands could bind to ciMC4R and initiate dose-dependent intracellular cyclic adenosine monophosphate (cAMP) accumulation.
    1 context sentence
    Summary · context
    The pharmacological properties of ciMC4R were investigated using 4 agonists, including α-melanocyte stimulating hormone (α-MSH), β-MSH, [Nle4, D-Phe7]-MSH (NDP-MSH), and adrenocorticotropic hormone (ACTH).
  3. 03LabIn vitro (cells)Activity measurement

    In assays of grass carp MC4R, NDP-MSH had higher potency than the endogenous agonists alpha-MSH and beta-MSH.

    In plain wordsIn lab tests, NDP-MSH was more potent at the grass carp MC4R receptor than the body's own agonists alpha-MSH and beta-MSH.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePotency at grass carp MC4R
    Study

    grass carp (receptor)n: not reported in source

    grass carp MC4R (ciMC4R) pharmacological assays
    Comparator
    alpha-MSH, beta-MSH
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both NDP-MSH and ACTH (1-24) exhibited higher potencies compared to the other 2 endogenous agonists.
    1 context sentence
    Summary · context
    The pharmacological properties of ciMC4R were investigated using 4 agonists, including α-melanocyte stimulating hormone (α-MSH), β-MSH, [Nle4, D-Phe7]-MSH (NDP-MSH), and adrenocorticotropic hormone (ACTH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.